Skip to main content

Glibenclamide plus metformin combination tablets are effective, convenient and well tolerated in the treatment of type 2 diabetes mellitus

Drugs & Therapy Perspectives volume 22, pages 1–6 (2006)Cite this article

Abstract

Combination therapy with an insulin-stimulating agent (i.e. glibenclamide [glyburide]) and an insulin-sensitising agent (i.e. metformin) is an optimal and rational therapeutic first- and second-line treatment in patients with type 2 diabetes mellitus. Single-tablet glibenclamide/metformin achieves better glycaemic control than monotherapy with either agent. The improved convenience of fixed-dose glibenclamide/metformin may improve patient compliance with treatment, thereby improving glycaemic control.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 49.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Table I
Table II

References

  1. International Diabetes Federation. Diabetes facts and figures [online]. Available from URL: http://www.idf.org [Accessed 2006 Jun 23]

  2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2005; 28 Suppl. 1: S37–42

    Article  Google Scholar 

  3. Hawkins D, Bradberry JC, Cziraky MJ, et al. National Pharmacy Cardiovascular Council treatment guidelines for the management of type 2 diabetes mellitus: toward better patient outcomes and new roles for pharmacists. Pharmacotherapy 2002 Apr; 22(4): 436–44

    Article  PubMed  Google Scholar 

  4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–53

    Article  Google Scholar 

  5. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–65

    Article  Google Scholar 

  6. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999; 16: 716–30

    Article  Google Scholar 

  7. American College of Endocrinology. Consensus statement on guidelines for glycemic control. Endocr Pract 2002 Jan–Feb; 8 Suppl. 1: 5–11

    Google Scholar 

  8. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004; 27 Suppl. 1: S15–35

    Google Scholar 

  9. Wolters Klower Health, Inc. Facts and Comparisons 4.0 [online]. Available from http://online.factsandcomparisons.com[Accessed 2006 Jun 23]

  10. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005–12

    Article  PubMed  CAS  Google Scholar 

  11. Guillausseau P-J. Impact of compliance with oral antihyperglycemic agents on health outcomes in type 2 diabetes mellitus: a focus on frequency of administration. Treat Endocrinol 2005; 4(3): 167–75

    Article  PubMed  CAS  Google Scholar 

  12. Chehade JM, Mooradian AD. Drug therapy: current and emerging agents. In: Sinclair AJ, Finucane P, editors. Diabetes in old age. 2nd ed. Chichester: John Wiley & Sons, 2001

    Google Scholar 

  13. Tosi F, Muggeo M, Brun E, et al. Combination treatment with metformin and glibenclamide versus single-drug therapies in type 2 diabetes mellitus: a randomised, double-blind, comparative study. Metabolism 2003 Jul; 52(7): 862–7

    Article  PubMed  CAS  Google Scholar 

  14. Howlett H, Porte F, Allavoine T, et al. The development of an oral antidiabetic combination tablet: design, evaluation and clinical benefits for patients with type 2 diabetes. Curr Med Res Opin 2003; 19(3): 218–25

    Article  PubMed  CAS  Google Scholar 

  15. Arezina R, Grune D. A single-blind four way cross-over study to assess the bioavailability of oral single doses of glibenclamide 5mg, metformin 500 mg, and two fixed combinations of glibenclamide 2.5 and 5mg and metformin 400 mg in 12 healthy male volunteers (Study 96549). Pisa: Laboratori Guidotti S.p.A., 1997. (Data on file)

  16. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995 Aug 31; 333(9): 541–9

    Google Scholar 

  17. UK Prospective Diabetes Study (UKPDS) Group. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care 1998 Jan; 21(1): 87–92

    Article  Google Scholar 

  18. Hermann LS, Schersten B, Melander A. Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination. Diabet Med 1994 Dec; 11(10): 953–60

    Article  PubMed  CAS  Google Scholar 

  19. Groop L, Widen E. Treatment strategies for secondary sulfonylurea failure. Should we start insulin or add metformin? Is there a place for intermittent insulin therapy? Diabete Metab 1991 May; 17 (1 Pt 2): 218–23

    PubMed  CAS  Google Scholar 

  20. Klein W. Sulfonylurea-metformin-combination versus sulfonylurea-insulin-combination in secondary failures of sulfonylurea monotherapy: results of a prospective randomized study in 50 patients. Diabete Metab 1991 May; 17 (1 Pt 2): 235–40

    PubMed  CAS  Google Scholar 

  21. Trischitta V, Italia S, Mazzarino S, et al. Comparison of combined therapies in treatment of secondary failure to glyburide. Diabetes Care 1992 Apr; 15(4): 539–42

    Article  PubMed  CAS  Google Scholar 

  22. Haupt E, Knick B, Koschiniski T, et al. Oral antidiabetic combination therapy with sulfonylureas and metformin. Diabete Metab 1991; 17 Suppl. 1; 224–31

    Google Scholar 

  23. Hermann LS, Schersten B, Bitzen PO, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: a double-blind controlled study. Diabetes Care 1994 Oct; 17(10): 1100–9

    Article  PubMed  CAS  Google Scholar 

  24. Cignarelli M, Giorgino R. Relazione della sperimentazione clinica controllata sullo studio degli effectti metabolici di una associazione glibencalmide metformina (Glibomet) versus glibenclamide nel trattamento del diabete mellito de tipo II. Pisa: Laboratori Guidotti S.p.A., 1984. (Data on File)

  25. D’Argenzio R, Cavallo P, Merante D, et al. Comparison of two treatment models in type-II diabetic patients with poor metabolic control: preformed combination of glibenclamide 2, 5 mg + metformin 400 mg or mono-therapy with sulfonylurea at maximal doses? An evaluation at six months [in Italian]. Minerva Endocrinol 1996 Sep; 21(3): 101–10

    PubMed  Google Scholar 

  26. Curiale V. Metformin plus glibenclamide versus glibenclamide in type II diabetic patients. Ann Exp Clin Med 1994; 1: 198–202

    Google Scholar 

  27. Pastore L, Morviducci L, Merante D et al. Combined glibenclamide plus metformin improves insulin sensitivity in non-obese type 2 diabetic patients. Diab Nutr Metab 1998; 11: 225–31

    CAS  Google Scholar 

  28. Garber AJ, Donovan Jr DS, Dandona P, et al. Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. J Clin Endocrinol Metab 2003 Aug; 88(8): 3598–604

    Article  PubMed  CAS  Google Scholar 

  29. Garber AJ, Bruce S, Fiedorek FT. Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study. Clin Ther 2002 Sep; 24(9): 1401–13

    Article  PubMed  CAS  Google Scholar 

  30. Garber AJ, Larsen J, Schneider SH, et al. Simultaneous glyburide/ metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes Metab 2002 May; 4(3): 201–8

    Article  PubMed  CAS  Google Scholar 

  31. Dailey III GE, Mohideen P, Fiedorek FT. Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study. Clin Ther 2002 Sep; 24(9): 1426–38

    Article  PubMed  CAS  Google Scholar 

  32. Melikian C, White TJ, Vanderplas A, et al. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002; 24: 460–7

    Article  PubMed  Google Scholar 

  33. Blonde L, Wogen J, Kreilick C, et al. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes Metab 2003 Nov; 5(6): 424–31

    Article  PubMed  CAS  Google Scholar 

  34. British national formulary. No. 51. London: The Pharmaceutical Press, 2006 Mar

  35. Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997 Dec; 103(6): 491–7

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy

    Giuseppe Derosa

Authors
  1. Giuseppe Derosa
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Derosa, G. Glibenclamide plus metformin combination tablets are effective, convenient and well tolerated in the treatment of type 2 diabetes mellitus. Drugs Ther. Perspect 22, 1–6 (2006). https://doi.org/10.2165/00042310-200622080-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200622080-00001

Keywords

  • Metformin
  • Glycaemic Control
  • Glibenclamide
  • Acarbose
  • Sulphonylurea